Ketogenic diets and Alzheimer's disease

Food Science and Human Wellness

Volumn 6, Issue 1, 2017, Pages 1-9

  Lange, Klaus W ^a   Lange, Katharina M ^b   Makulska Gertruda, Ewelina ^a   Nakamura, Yukiko ^a   Reissmann, Andreas ^a   Kanaya, Shigehiko ^c   Hauser, Joachim ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF WINCHESTER   (United Kingdom)

^c NARA INSTITUTE OF SCIENCE AND TECHNOLOGY   (Japan)

Author keywords

Alzheimer's disease; Ketogenic diet; Ketone bodies; Therapy

Indexed keywords

EID: 85068991767     PISSN: None     EISSN: 22134530     Source Type: Journal    
DOI: 10.1016/j.fshw.2016.10.003     Document Type: Review

References (80)

1. Scheltens, P., Blennow, K., Breteler, M.M.B., de Strooper, B., Frisoni, G.B., Salloway, S., Van der Flier, W.M., Alzheimer's disease. Lancet 388 (2016), 505–517.
2. Burns, A., Iliffe, S., Alzheimer's disease. BMJ, 338, 2009, b158.
3. Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro Wagner, F., Cleusa, P., The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 9 (2013), 63–75 e2.
4. Gottesman, R.F., Schneider, A.L., Albert, M., Alonso, A., Bandeen-Roche, K., Coker, L., Coresh, J., Knopman, D., Power, M.C., Rawlings, A., Sharrett, R., Wruck, L.M., Mosley, T.H., Midlife hypertension and 20-year cognitive change: the atherosclerosis risk in communities neurocognitive study. JAMA Neurol. 71 (2014), 1218–1227.
5. Nyberg, J., Aberg, M.A., Schiöler, L., Nilsson, M., Wallin, A., Torén, K., Kuhn, H.G., Cardiovascular and cognitive fitness at age 18 and risk of early-onset dementia. Brain 137 (2014), 1514–1523.
6. Norton, S., Matthews, F.E., Barnes, D.E., Yaffe, K., Brayne, C., Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. Lancet Neurol. 13 (2014), 788–794.
7. Hyman, B.T., Phelps, C.H., Beach, T.G., Bigio, E.H., Cairns, N.J., Carrillo, M.C., Dickson, D.W., Duyckaerts, C., Frosch, M.P., Masliah, E., Mirra, S.S., Nelson, P.T., Schneider, J.A., Thal, D.R., Thies, B., Trojanowski, J.Q., Vinters, H.V., Montine, T.J., National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 8 (2012), 1–13.
8. Karran, E., Mercken, M., De Strooper, B., The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 10 (2011), 698–712.
9. Duff, K., Small, S.A., Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron, 60, 2008.
10. Guerreiro, R., Hardy, J., Genetics of Alzheimer's disease. Neurotherapeutics 11 (2014), 732–737.
11. Kalmijn, S., Launer, L.J., Ott, A., Witteman, J.C., Hofman, A., Breteler, M.M., Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann. Neurol. 59 (2002), 1915–1921.
12. Engelhart, M.J., Geerlings, M.I., Ruitenberg, A., van Swieten, J.C., Hofman, A., Witteman, J.C., Breteler, M.M., Diet and risk of dementia: Does fat matter?: The Rotterdam Study. Neurology 59 (2002), 1915–1921.
13. Morris, M.C., Evans, D.A., Bienias, J.L., Tangney, C.C., Wilson, R.S., Dietary fat intake and 6-year cognitive change in an older biracial community population. Neurology 62 (2004), 1573–1579.
14. Gillette-Guyonnet, S., Vellas, B., Caloric restriction and brain function. Curr. Opin. Clin. Nutr. Metab. Care. 11 (2008), 686–692.
15. Cremer, J.E., Braun, L.D., Oldendorf, W.H., Changes during development in transport processes of the blood-brain barrier. Biochim. Biophys. Acta 448 (1976), 633–637.
16. Morris, A.A., Cerebral ketone body metabolism. J. Inherit. Metab. Dis. 28 (2005), 109–121.
17. Chowdury, G.M., Jiang, L., Rothman, D.L., Behar, K.L., The contribution of ketone bodies to basal and activity-dependent neuronal oxidation in vivo. J. Cereb. Blood Flow Metab. 34 (2014), 1233–1242.
18. Owen, O.E., Morgan, A.P., Kemp, H.G., Sullivan, J.M., Herrera, M.G., Cahill, G.F. Jr., Brain metabolism during fasting. J. Clin. Invest. 46 (1967), 1589–1595.
19. Cordain, L., Eades, M.R., Eades, M.D., Hyperinsulinemic diseases of civilization: more than just Syndrome X. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 136 (2003), 94–112.
20. Hellerstein, M.K., Carbohydrate-induced hypertriglyceridemia: modifying factors and implications for cardiovascular risk. Curr. Opin. Lipidol. 13 (2002), 33–40.
21. Henderson, S.T., High carbohydrate diets and Alzheimer's disease. Med. Hypotheses 62 (2004), 689–700.
22. Kossoff, E.H., More fat and fewer seizures: dietary therapies for epilepsy. Lancet Neurol. 3 (2004), 415–420.
23. Bailey, E.E., Pfeifer, H.H., Thiele, E.A., The use of diet in the treatment of epilepsy. Epilepsy Behav. 6 (2005), 4–8.
24. Cunnane, S., Nugent, S., Roy, M., Courchesne-Loyer, A., Croteau, E., Tremblay, S., Castellano, A., Pifferi, F., Bocti, C., Paquet, N., Begdouri, H., Bentourkia, M., Turcotte, E., Allard, M., Barberger-Gateau, P., Fulop, T., Rapoport, S., Brain fuel metabolism, aging, and Alzheimer's disease. Nutrition 27 (2011), 3–20.
25. Vining, E.P., Freeman, J.M., Ballaban-Gil, K., Camfield, C.S., Camfield, P.R., Holmes, G.L., Shinnar, S., Schuman, R., Trevathan, E., Wheless, J.W., A multicenter study of the efficacy of the ketogenic diet. Arch. Neurol. 55 (1998), 1433–1437.
26. Sinha, S.R., Kossoff, E.H., The ketogenic diet. Neurologist 11 (2005), 161–170.
27. Barañano, K.W., Hartman, A.L., The ketogenic diet: uses in epilepsy and other neurologicai llnesses. Curr. Treat Options Neurol. 10 (2008), 410–419.
28. Freeman, J., Veggiotti, P., Lanzi, G., Tagliabue, A., Perucca, E., The ketogenic diet: from molecular mechanisms to clinical effects. Epilepsy Res. 68 (2006), 145–180.
29. Bough, K.J., Rho, J., Anticonvulsant mechanisms of the ketogenic diet. Epilepsia 48 (2007), 43–58.
30. Ma, W., Berg, J., Yellen, G., Ketogenic diet metabolites reduce firing in central neurons by opening K (ATP) channels. J. Neurosci. 27 (2007), 3618–3625.
31. Bak, L.K., Schousboe, A., Sonnewald, U., Waagepetersen, H.S., Glucose is necessary to maintain neurotransmitter homeostasis during synaptic activity in cultured glutamatergic neurons. J. Cereb. Blood Flow Metab. 26 (2006), 1285–1297.
32. Hertz, L., Chen, Y., Waagepetersen, H.S., Effects of ketone bodies in Alzheimer's disease in relation to neural hypometabolism, β-amyloid toxicity, and astrocyte function. J. Neurochem. 134 (2015), 7–20.
33. Lund, T.M., Risa, O., Sonnewald, U., Schousboe, A., Waagepetersen, H.S., Availability of neurotransmitter glutamate is diminished when beta-hydroxybutyrate replaces glucose in cultured neurons. J. Neurochem. 110 (2009), 80–91.
34. Paoli, A., Bianco, A., Damiani, E., Bosco, G., Ketogenic diet in neuromuscular and neurodegenerative diseases. BioMed. Res. Int., 2014, 2014, 474296.
35. Frackowiak, R.S., Pozzilli, C., Legg, N.J., Du Boulay, G.H., Marshall, J., Lenzi, G.L., Jones, T., Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography. Brain 104 (1981), 753–778.
36. Mosconi, L., Brys, M., Glodzik-Sobanska, L., De Santi, S., Rusinek, H., de Leon, M.J., Early detection of Alzheimer's disease using neuroimaging. Exp. Gerontol. 42 (2007), 129–138.
37. de Leon, M.J., Ferris, S.H., George, A.E., Christman, D.R., Fowler, J.S., Gentes, C., Reisberg, B., Gee, B., Emmerich, M., Yonekura, Y., Brodie, J., Kricheff, I.I., Wolf, A.P., Positron emission tomographic studies of aging and Alzheimer disease. AJNR Am. J. Neuroradiol. 4 (1983), 568–571.
38. Mosconi, L., De Santi, S., Li, J., Tsui, W.H., Li, Y., Boppana, M., Laska, E., Rusinek, H., de Leon, M.J., Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol. Aging 29 (2008), 676–692.
39. Chen, K., Ayutyanont, N., Langbaum, J.B., Fleisher, A.S., Reschke, C., Lee, W., Liu, X., Bandy, D., Alexander, G.E., Thompson, P.M., Shaw, L., Trojanowski, J.Q., Jack, C.R., Landau, S.M., Foster, N.L., Harvey, D.J., Weiner, M.W., Koeppe, R.A., Jagust, W.J., Reiman, E.M., Characterizing Alzheimer's disease using a hypometabolic convergence index. Neuroimage 56 (2011), 52–60.
40. Cunnane, S.C., Courchesne-Loyer, A., St-Pierre, V., Vandenberghe, C., Pierotti, T., Fortier, M., Croteau, E., Castellano, C.A., Can ketones compensate for deteriorating brain glucose uptake during aging? Implications for the risk and treatment of Alzheimer's disease. Ann. N. Y. Acad. Sci. 1367 (2016), 12–20.
41. Gannon, M., Che, P., Chen, Y., Jiao, K., Roberson, E.D., Wang, Q., Noradrenergic dysfunction in Alzheimer's disease. Front. Neurosci., 9, 2015, 220.
42. Reiman, E.M., Chen, K., Alexander, G.E., Caselli, R.J., Bandy, D., Osborne, D., Saunders, A.M., Hardy, J., Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 8299–8302.
43. Reiman, E.M., Chen, K., Alexander, G.E., Caselli, R.J., Bandy, D., Osborne, D., Saunders, A.M., Hardy, J., Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 284–289.
44. Dukart, J., Mueller, K., Villringer, A., Kherif, F., Draganski, B., Frackowiak, R., Schroeter, M.L., Relationship between imaging biomarkers age, progression and symptom severity in Alzheimer's disease. Neuroimage Clin. 3 (2013), 84–94.
45. Mosconi, L., Brys, M., Switalski, R., Mistur, R., Glodzik, L., Pirraglia, E., Tsui, W., de Santi, S., de Leon, M.J., Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 19067–19072.
46. Drenick, E.J., Alvarez, L.C., Tamasi, G.C., Brickman, A.S., Resistance to symptomatic insulin reactions after fasting. J. Clin. Invest. 51 (1972), 2757–2762.
47. Sato, K., Kashiwaya, Y., Keon, C.A., Tsuchiya, N., King, M.T., Radda, G.K., Veech, R.L., Insulin ketone bodies, and mitochondrial energy transduction. FASEB J. 9 (1995), 651–658.
48. Veech, R.L., The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot. Essent. Fatty Acids 70 (2004), 309–319.
49. Kashiwaya, Y., King, M.T., Veech, R.L., Substrate signaling by insulin: a ketone bodies ratio mimics insulin action in heart. Am. J. Cardiol. 80 (1997), 50A–64A.
50. Castellano, C.A., Nugent, S., Paquet, N., Tremblay, S., Bocti, C., Lacombe, G., Imbeault, H., Turcotte, E., Fulop, T., Cunnane, S.C., Lower brain 18F-fluorodeoxyglucose uptake but normal 11Cacetoacetate metabolism in mild Alzheimer's disease dementia. J. Alzheimers Dis. 43 (2015), 1343–1353.
51. Maalouf, M., Rho, J.M., Mattson, M.P., The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. Brain Res. Rev. 59 (2009), 293–315.
52. Ingram, D.K., Zhu, M., Mamczarz, J., Zou, S., Lane, M.A., Roth, G.S., deCabo, R., Calorie restriction mimetics: an emerging research field. Aging Cell 5 (2006), 97–108.
53. Kashiwaya, Y., Takeshima, T., Mori, N., Nakashima, K., Clarke, K., Veech, R.L., D-Beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 5440–5444.
54. LaFerla, F.M., Green, K., Animal models of Alzheimer disease. Cold Spring Harb. Perspect. Med., 2, 2012.
55. Van der Auwera, I., Wera, S., van Leuven, F., Henderson, S.T., A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease. Nutr. Metab., 2, 2005, 28.
56. Moechars, D., Dewachter, I., Lorent, K., Reversé, D., Baekelandt, V., Naidu, A., Tesseur, I., Spittaels, K., van Den Haute, C., Checler, F., Godaux, E., Cordell, B., van Leuven, F., Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 274 (1999), 6483–6492.
57. Brownlow, M.L., Benner, L., D'Agostino, D., Gordon, M.N., Morgan, D., Ketogenic diet improves motor performance but not cognition in two mouse models of Alzheimer's pathology. PLoS One, 8, 2013, e75713.
58. Halagappa, V.K., Guo, Z., Pearson, M., Matsuoka, Y., Cutler, R.G., Laferla, F.M., Mattson, M.P., Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 26 (2007), 212–220.
59. Studzinski, C.M., MacKay, W.A., Beckett, T.L., Henderson, S.T., Murphy, M.P., Sullivan, P.G., Burnham, W.M., Induction of ketosis may improve mitochondrial function and decrease steady-state amyloid-beta precursor protein (APP) levels in the aged dog. Brain Res. 1226 (2008), 209–217.
60. Swerdlow, R.H., The neurodegenerative mitochondriopathies. J. Alzheimers Dis. 17 (2009), 737–751.
61. Soane, L., Kahraman, S., Kristian, T., Fiskum, G., Mechanisms of impaired mitochondrial energy metabolism in acute and chronic neurodegenerative disorders. J. Neurosci. Res. 85 (2007), 3407–3415.
62. Yao, J., Irwin, R.W., Zhao, L., Nilsen, J., Hamilton, R.T., Brinton, R.D., Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 14670–14675.
63. Yao, J., Chen, S., Mao, Z., Cadenasm, E., Brinton, R.D., 2-Deoxy-D-glucose treatment induces ketogenesis, sustains mitochondrial function, and reduces pathology in female mouse model of Alzheimer's disease. PLoS One, 6, 2011, e21788.
64. Kashiwaya, Y., Bergman, C., Lee, J.H., Wan, R., King, M.T., Mughal, M.R., Okun, E., Clarke, K., Mattson, M.P., Veech, R.L., A ketone ester diet exhibits anxiolytic and cognition-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer's disease. Neurobiol. Aging 34 (2013), 1530–1539.
65. Aso, E., Semakova, J., Joda, L., Semak, V., Halbaut, L., Calpena, A., Escolano, C., Perales, J.C., Ferrer, I., Triheptanoin supplementation to ketogenic diet curbs cognitive impairment in APP/PS1 mice used as a model of familial Alzheimer's disease. Alzheimer Res. 10 (2013), 290–297.
66. Reger, M.A., Henderson, S.T., Hale, C., Cholerton, B., Baker, L.D., Watson, G.S., Hyde, K., Chapman, D., Craft, S., Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol. Aging 25 (2004), 311–314.
67. Bach, A.C., Babayan, V., Medium-chain triglycerides: an update. Am. J. Clin. Nutr. 36 (1982), 950–962.
68. Henderson, S.T., Vogel, J.L., Barr, L.J., Garvin, F., Jones, J.J., Costantini, L.C., Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr. Metab. (Lond.), 6, 2009, 31.
69. Henderson, S.T., Poirier, J., Pharmacogenetic analysis of the effects of polymorphisms in APOE IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease; a randomized, double-blind, placebo-controlled study. BMC Med. Genet., 12, 2011, 137.
70. ®) in the treatment of mild to moderate Alzheimer's disease. Am. J. Alzheimers Dis. Other Demen. 29 (2014), 409–414.
71. Krikorian, R., Shidler, M.D., Dangelo, K., Couch, S.C., Benoit, S.C., Clegg, D.J., Dietary ketosis enhances memory in mild cognitive impairment. Neurobiol. Aging, 33, 2012 425. e19-27.
72. Newport, M.T., VanItallie, T.B., Kashiwaya, Y., King, M.T., Veech, R.L., A new way to produce hyperketonemia: use of ketone ester in a case of Alzheimer's disease. Alzheimers Dement. 11 (2015), 99–103.
73. Clarke, K., Tchabanenko, K., Pawlosky, R., Carter, E., Todd King, M., Musa-Veloso, K., Ho, M., Roberts, A., Robertson, J., Vanitallie, T.B., Veech, R.L., Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects. Regul. Toxicol. Pharmacol. 63 (2012), 401–408.
74. Krebs, H.A., The regulation of the release of ketone bodies by the liver. Adv. Enzyme Regul. 4 (1966), 339–353.
75. Dashti, H.M., Mathew, T.C., Hussein, T., Asfar, S.K., Behbahani, A., Khoursheed, M.A., Al-Sayer, H.M., Bo-Abbas, Y.Y., Al-Zaid, N.S., Long-term effects of a ketogenic diet in obese patients. Exp. Clin. Cardiol. 9 (2004), 200–205.
76. Wolf-Klein, G.P., Silverstone, F.A., Levy, A.P., Sweet cravings and Alzheimer's disease. J. Am. Geriatr. Soc. 39 (1991), 535–536.
77. Greenwood, C.E., Tam, C., Chan, M., Young, K.W., Binns, M.A., van Reekum, R., Behavioral disturbances not cognitive deterioration, are associated with altered food selection in seniors with Alzheimer's disease. J. Gerontol. A Biol. Sci. Med. Sci. 60 (2005), 499–505.
78. Levin-Allerhand, A., Lominska, C.E., Smith, J.D., Increased amyloidlevels in APPSWE transgenic mice treated chronically with a physiological high-fat high-cholesterol diet. J. Nutr. Health Aging 6 (2002), 315–319.
79. Ho, L., Qin, W., Pompl, P.N., Xiang, Z., Wang, J., Zhao, Z., Peng, Y., Cambareri, G., Rocher, A., Mobbs, C.V., Hof, P.R., Pasinetti, G.M., Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 18 (2004), 902–904.
80. Vanitallie, T.B., Preclinical sporadic Alzheimer's disease: target for personalized diagnosis and preventive intervention. Metabolism 62:Suppl. 1 (2013), S30–S33.